Regenxbio Inc (RGNX)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.84 | 1.75 | 1.68 | 1.61 | 1.61 | 1.57 | 1.51 | 1.49 | 1.46 | 1.73 | 1.65 | 1.59 | 1.87 | 1.30 | 1.13 | 1.10 | 1.11 | 1.09 | 1.07 | 1.07 |
Based on the data provided, Regenxbio Inc has consistently maintained a very healthy solvency position over the past eight quarters. The debt-to-assets, debt-to-capital, and debt-to-equity ratios have all consistently remained at 0.00, indicating that the company has no debt relative to its assets, capital, or equity. This suggests that Regenxbio's operations are primarily funded through equity and retained earnings rather than debt financing.
Furthermore, the financial leverage ratio has shown a gradual increasing trend over the quarters, with the ratio reaching 1.84 in Q4 2023 compared to 1.49 in Q1 2022. While the increase in the financial leverage ratio indicates a slight increase in the company's reliance on debt financing, the overall level remains relatively low, indicating a conservative approach to leveraging.
In conclusion, based on the solvency ratios provided, Regenxbio Inc appears to have a very strong financial position with minimal debt levels and a conservative approach to leverage, which bodes well for the company's long-term financial health and stability.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -39.07 | -26.50 | -18.70 | -12.71 | -11.06 | 4.42 | 4.97 | 5.46 | 6.38 | -9.74 | -9.71 | -16.72 | -154.65 | — | — | — | — | — | — | — |
The interest coverage ratio measures a company's ability to meet its interest obligations with its operating income. A higher interest coverage ratio indicates a stronger ability to cover interest expenses.
Regenxbio Inc's interest coverage has been fluctuating significantly over the past eight quarters. The data shows a negative trend with the ratio declining from 5.32 in Q1 2022 to -39.22 in Q4 2023, indicating a deterioration in the company's ability to cover its interest expenses with operating income.
The negative values in Q2 2022, Q3 2022, and Q4 2022 suggest that the company's operating income was insufficient to cover its interest expenses during those periods. The subsequent positive ratios in Q1 2023 and Q2 2023 were not sustained, as the ratio turned negative again in Q3 2023 and Q4 2023.
Overall, the consistently negative interest coverage ratios raise concerns about Regenxbio Inc's financial health and ability to service its debt obligations. It indicates a potential risk factor for investors and creditors, signaling the need for the company to closely monitor and manage its financial obligations to avoid potential financial distress.